SAN FRANCISCO — Invitae, a Bay Area genetic testing company with a mission to use genomic information to improve health care, has struggled to turn that mantra into a solid business model. It’s now ...

Invitae Corporation (NYSE:NVTA) shares are trading lower this Wednesday after the company reported fourth-quarter financial results and provided guidance for full-year 2023. The company also announced ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Invitae CEO Ken Knight takes the ...

We are in the early days of precision medicine but it is on the back of widespread gene testing that promise of this approach of treating diseases stands. And there are plenty of companies offering ...

SAN FRANCISCO--(BUSINESS WIRE)--Invitae Corporation (NYSE:NVTA), a genetic information company, today announced that it has expanded its genetic testing offering with hundreds of additional genes and ...

San Francisco-headquartered Invitae Corp NVTA defines itself as medical genetics company seeking to bring comprehensive genetic information into mainstream medicine, with the goal of improving ...

Invitae grew revenue by 65% in 2021. The company also had an earnings-per-share loss of $1.80 last year. The company didn't release any news on Monday, but its stock has been steadily climbing over ...

Genetic testing company Invitae has made more than a dozen acquisitions to further its goal of democratizing genetic testing. Its latest deal, a $325 million bid to acquire Ciitizen, will add patients ...

A genetics testing company is launching a new database where patients can contribute information that could be used to research certain diseases. Invitae, the company behind the Patient Insights ...

Invitae missed analysts' Q1 revenue and net loss estimates. The bigger concern for the company, though, is its cash burn. Invitae reported first-quarter revenue of $123.7 million, up 19.4% year over ...